Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Immune Response to GeneVac-B® (rDNA I.P. Hepatitis B Vaccine) in Vaccinated Persons with a Standard Schedule in Bobo-Dioulasso, Burkina Faso

Mathuola Nina Genéviève OUATTARA
,
Armel Moumouni Sanou
* ORCID logo ,
Delphine NAPON-ZONGO
ORCID logo ,
Abou Coulibaly
ORCID logo ,
Sylviane KORGO
,
Abdoulaye DERA
,
NIKIEMA Sindimbasba Achille
,
Eric KYELEM
,
Nawatou GANSORE
,
Abdoul Kader ILBOUDO
,
Jeoffray Diendéré
ORCID logo ,
Henri Gautier OUEDRAOGO
Version 1 : Received: 3 May 2024 / Approved: 7 May 2024 / Online: 7 May 2024 (08:17:39 CEST)

How to cite: OUATTARA, M. N. G.; Sanou, A. M.; NAPON-ZONGO, D.; Coulibaly, A.; KORGO, S.; DERA, A.; Achille, N. S.; KYELEM, E.; GANSORE, N.; ILBOUDO, A. K.; Diendéré, J.; OUEDRAOGO, H. G. Immune Response to GeneVac-B® (rDNA I.P. Hepatitis B Vaccine) in Vaccinated Persons with a Standard Schedule in Bobo-Dioulasso, Burkina Faso. Preprints 2024, 2024050333. https://doi.org/10.20944/preprints202405.0333.v1 OUATTARA, M. N. G.; Sanou, A. M.; NAPON-ZONGO, D.; Coulibaly, A.; KORGO, S.; DERA, A.; Achille, N. S.; KYELEM, E.; GANSORE, N.; ILBOUDO, A. K.; Diendéré, J.; OUEDRAOGO, H. G. Immune Response to GeneVac-B® (rDNA I.P. Hepatitis B Vaccine) in Vaccinated Persons with a Standard Schedule in Bobo-Dioulasso, Burkina Faso. Preprints 2024, 2024050333. https://doi.org/10.20944/preprints202405.0333.v1

Abstract

GeneVac-B® was recently licensed in Burkina Faso and is widely used for population vaccination. This study aimed to evaluate the immune response in people fully vaccinated against hepatitis B with the GeneVac-B® vaccine in Burkina Faso under actual conditions of use. This cross-sectional study included individuals fully vaccinated with GeneVac-B®. For each consenting participant, sociodemographic and clinical data were collected using a structured questionnaire. Approximately 4 mL of whole blood was collected for immunological (anti-HBs, HBsAg, anti-HCV and anti-HIV) and biochemical (blood glucose, total cholesterol, and triglycerides) testing. The anti-HBs titer was used to determine the immune response. A total of 392 participants were included in the study. The mean age was 35.5±15 years. Approximately 56.1% had been previously exposed to HBV. Three hundred eighty (380) participants had an anti-HBs titer ≥ 12 mIU/mL, a seroprotection rate of 96.9%, and 12 had a titer < 12 mIU/mL, a nonresponse rate of 3.1%. Among the nonresponders, 11 (11/12; 91.7%) had high total cholesterol levels (> 240 mg/dL), and 8 (8/12; 66.7%) were older than 40 years of age. The results showed an excellent immune response to GeneVac-B® in our study population. However, age > 40 and high total cholesterol appear to be factors associated with nonresponse.

Keywords

Hepatitis B; GeneVac-B®; Immune response; Nonresponse factors; Burkina Faso

Subject

Biology and Life Sciences, Immunology and Microbiology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.